Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLA‐B</i> Genotypes and Phenytoin Dosing: 2020 Update
2020/08/12 by Jason H. Karnes, Allan E. Rettie, Andrew A. Somogyi +13 · 26 citations
Medicine · Pharmacology, Toxicology and Pharmaceutics · #Drug-Induced Adverse Reactions #Pharmaceutical studies and practices #Pharmacovigilance and Adverse Drug Reactions
paper · pdf · doi:10.1002/cpt.2008
Abstract
Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).
Cited by
- Cytochrome P450 Enzymes and Drug Metabolism in Humans
- Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. [europepmc]
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital. [europepmc]
- PharmVar GeneFocus: CYP2C9. [europepmc]
- Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population. [europepmc]
- Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions. [europepmc]
- Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine. [europepmc]
- Massively parallel characterization of CYP2C9 variant enzyme activity and abundance. [europepmc]
- Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients. [europepmc]
- Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects. [europepmc]
- Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial. [europepmc]
- Genetic Findings as the Potential Basis of Personalized Pharmacotherapy in Phelan-McDermid Syndrome. [europepmc]
- Association of HLA-B*51:01, HLA-B*55:01 , CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population. [europepmc]
- Cytochrome P450 Enzymes and Drug Metabolism in Humans. [europepmc]
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. [europepmc]
- A population study of clinically actionable genetic variation affecting drug response from the Middle East. [europepmc]
- Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data. [europepmc]
- Pharmacogenetics in Primary Headache Disorders. [europepmc]
- Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. [europepmc]
- Pharmacogenomics in Psychiatry Practice: The Value and the Challenges. [europepmc]
- Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. [europepmc]
- Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank. [europepmc]
- Impact of Pharmacogenomics in Clinical Practice. [europepmc]
- Intranasal delivery of phenytoin loaded layered double hydroxide nanoparticles improves therapeutic effect on epileptic seizures. [europepmc]
- Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. [europepmc]
- Severe cutaneous adverse reactions. [europepmc]
Related